Dopamine modulates exocytosis independent of Ca(2+) entry in melanotropic cells.
Dopamine is a known inhibitor of pituitary melanotropic cells. It reduces Ca(2+) influx by hyperpolarizing the cell membrane and by modulating high- and low-voltage-activated (HVA and LVA) Ca(2+) channels. As a result, dopamine reduces the hormonal output of the cell. However, it is unknown how dopamine affects each of the four different HVA Ca(2+) channel types individually. Moreover, it is unknown whether dopamine interacts with exocytosis independent of Ca(2+) channels. Here we show that dopamine differentially modulates the HVA Ca(2+) channels and that it affects the stimulus-secretion coupling through a direct effect on the exocytotic machinery. Sustained L- and P-type Ba(2+) currents are reduced in amplitude and inactivating N- and Q-type currents acquire different activation and inactivation kinetics in the presence of dopamine. The Q-type current shows slow activation, which is a hallmark for direct G-protein modulation. We used membrane capacitance measurements to monitor exocytosis. Surprisingly, we find that the amount of exocytosis per step depolarization is not diminished by dopamine despite the reduction in Ca(2+) current. To test whether dopamine affects the release machinery downstream of Ca(2+) entry, we stimulated exocytosis by dialyzing cells with buffered high-Ca(2+) solutions. Dopamine increased the amount and the rate of exocytosis. In the first 90 s, the rate of secretion was increased two- to threefold, but it was normalized again at 180 s, suggesting that predominantly vesicles that fuse early in the exocytotic phase are modulated by dopamine. Thus while Ca(2+) channels are inhibited by dopamine, the exocytotic machinery downstream of Ca(2+) influx is sensitized. As a result, release is more effectively stimulated by Ca(2+) influx during dopamine inhibition.
Mansvelder
Huibert D
HD
Research Institute Neurosciences, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands. hm2006@columbia.edu
Lodder
Johannes C
JC
Sons
Michèle S
MS
Kits
Karel S
KS
D060848:Agatoxins; D000818:Animals; D001464:Barium / Q000493:pharmacokinetics; D002118:Calcium / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D020746:Calcium Channels, L-Type / Q000378:metabolism; D020865:Calcium Channels, P-Type / Q000378:metabolism; D002478:Cells, Cultured; D004298:Dopamine / Q000494:pharmacology*; D005089:Exocytosis / Q000187:drug effects* / Q000502:physiology; D008297:Male; D020460:Melanosomes / Q000378:metabolism; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D009553:Nimodipine / Q000494:pharmacology; D010902:Pituitary Gland / Q000166:cytology* / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013111:Spider Venoms / Q000494:pharmacology
D060848:Agatoxins; D002121:Calcium Channel Blockers; D020746:Calcium Channels, L-Type; D020865:Calcium Channels, P-Type; D013111:Spider Venoms; C060465:omega-agatoxin I; D001464:Barium; D009553:Nimodipine; D002118:Calcium; D004298:Dopamine